Table 5

MBL2 diplotypes and odds ratio for risk of being HCV RNA negative among injection drug users

European Americans

African Americans



Diplotype

HCV RNA Negative

HCV RNA Positive

OR (95% CI)

OR (95% CI)*

HCV RNA Negative

HCV RNA Positive

OR (95% CI)

OR (95% CI)*


YA/YA

32.1%

37.8%

1.00

1.00

30.3%

31.3%

1.00

1.00

XA/YA

25.7%

22.7%

1.36 (0.77–2.43)

1.36 (0.77–2.43)

18.0%

18.1%

1.01 (0.50–2.05)

1.01 (0.50–2.05)

YA/YO

16.5%

24.1%

0.81 (0.43–1.55)

0.99 (0.77–1.79)

29.2%

31.0%

0.96 (0.52–1.78)

1.00 (0.55–1.83)

XA/XA

5.5%

2.3%

2.74 (0.88–8.52)


2.3%

1.3%

2.08 (0.35–12.21)


XA/YO

12.8%

7.3%

2.31 (1.07–5.02)

2.00

7.9%

10.0%

0.82 (0.33–2.08)

1.13

YO/YO

7.3%

5.8%

1.61 (0.65–4.03)

(1.05–3.82)

12.4%

8.4%

1.49 (0.65–3.41)

(0.57–2.24)


*OR for grouped diplotypes. Diplotypes were ordered and grouped on the basis of previously reported serum MBL levels among Caucasians [13]. Mean serum MBL [mg/l] in that report were: YA/YA, 4.78; XA/YA, 2.83; YA/YO, 1.58; XA/XA, 1.39; XA/YO, 0.19; YO/YO, 0.05.

Brown et al. BMC Infectious Diseases 2008 8:57   doi:10.1186/1471-2334-8-57

Open Data